Xanra 60 mg

"Healing of Erosive Esophagitis: Xanra is indicated for the healing of all grades of erosive esophagitis (EE) for up to 8 weeks. Maintenance of Healed Erosive Esophagitis: Xanra is indicated to maintain healing of EE and relief of heartburn for up to 6 months. Symptomatic Non-Erosive Gastroesophageal Reflux Disease: Xanra is indicated for the treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD) for 4 weeks. * \u09b0\u09c7\u099c\u09bf\u09b8\u09cd\u099f\u09be\u09b0\u09cd\u09a1 \u099a\u09bf\u0995\u09bf\u09ce\u09b8\u0995\u09c7\u09b0 \u09aa\u09b0\u09be\u09ae\u09b0\u09cd\u09b6 \u09ae\u09cb\u09a4\u09be\u09ac\u09c7\u0995 \u0994\u09b7\u09a7 \u09b8\u09c7\u09ac\u09a8 \u0995\u09b0\u09c1\u09a8'"

"Dexlansoprazole delayed-release capsule is a Proton Pump Inhibitor (PPI) which suppresses gastric acid secretion by specific inhibition of the (H+\/K+)-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Dexlansoprazole blocks the final step of acid production. It is the R-enantiomer of lansoprazole (A racemic mixture of the R- and S-enantiomers). Dexlansoprazole is supplied as a Dual Delayed Release (DDR) formulation in a capsule for oral administration. This capsule contains a mixture of two types of enteric coated granules with different pH-dependent dissolution profiles. The dual delayed release formulation in dexlansoprazole, plasma concentration-time profile with two distinct peaks; the first peak occurs 1 to 2 hours after administration, followed by a second peak within 4 to 5 hours. After oral administration, mean Cmax and AUC value of Dexlansoprazole increased approximately dose proportionally. Dexlansoprazole is extensively metabolized in the liver and excreated by urine."

"Dexlansoprazole dosing recommendations- Maintenance of Healed erosive esophagitis and relief of heartburn: 30 mg Once daily Symptomatic Non-Erosive GERD: 30 mg Once daily for 4 weeks Healing of erosive esophagitis: 60 mg Once daily for up to 8 weeks Dexlansoprazole MUPS dosing recommendations- Maintenance of healed erosive esophagitis and relief of heartburn: One 30 mg tablet once daily for 6 months in adults and 16 weeks in patients 12 to 17 years of age Symptomatic Non-Erosive GERD: One 30 mg tablet once daily for 4 weeks * \u09b0\u09c7\u099c\u09bf\u09b8\u09cd\u099f\u09be\u09b0\u09cd\u09a1 \u099a\u09bf\u0995\u09bf\u09ce\u09b8\u0995\u09c7\u09b0 \u09aa\u09b0\u09be\u09ae\u09b0\u09cd\u09b6 \u09ae\u09cb\u09a4\u09be\u09ac\u09c7\u0995 \u0994\u09b7\u09a7 \u09b8\u09c7\u09ac\u09a8 \u0995\u09b0\u09c1\u09a8'"

"With medicine: Atazanavir, Warfarin, Tacrolimus, Clopidogrel & Methotrexate. With food & others: No data available."

"Common side effects: Diarrhea, abdominal pain, nausea, vomiting & flatulence."

"Pregnancy Category B. There is no adequate and well-controlled studies with Dexlansoprazole in pregnant women. There is no adequate and well-controlled studies with Dexlansoprazole in Lactating mother."

"Gastric Malignancy, Clostridium difficile Associated Diarrhea, Bone fracture, Hypomagnesemia, and concomitant use of Xanra with Methotrexate."